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OBJECTIVE
To investigate the impact of metabolic response measured by 18-fluorodeoxyglucose positron emission 
tomography and computed tomography (FDG-PET-CT) in patients with breast cancer liver metastasis 
(BCLM) treated with stereotactic body radiotherapy (SBRT).
METHODS
The medical records of 17 patients with BCLM treated with SBRT between March 2013 and October 2017 
were investigated retrospectively. Patients received SBRT for their liver metastasis, and thereafter, a second 
FDG-PET-CT was performed for response assessment in a median of 4.1 (2.2–8.2) months. A total of 54 
Gy in three fractions were delivered to liver metastatic lesions. The standardized uptake value (SUV) and 
survival rates were evaluated.
RESULTS
After a median follow-up time of 11.5 (3.2–48.9) months, there was a significant difference between pre- 
and post-SBRT SUVs (p<0.001). Complete metabolic response was observed in 14 (82%) patients, partial 
metabolic response was observed in 2 (12%) patients, and stable metabolic disease/progressive metabolic 
disease was observed in 1 (6%) patient at post-treatment PET-CT. The 1- and 2-year overall survival rates 
were 68% and 57%, respectively, and the 1- and 2-year progression-free survival rates were 38% and 25%, 
respectively.
CONCLUSION
PET-CT is an effective tool for response monitoring in patients with BCLM treated with SBRT.
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Introduction 
The liver is one of the most common metastatic sites 
for many cancer types, and liver metastasis (LM) is a 
substantial cause of morbidity and mortality.[1] Lo-
cal treatment options for LM are surgery, transarterial 
chemoembolization (TACE), radiofrequency ablation 
(RFA), and radiotherapy (RT). These local treatments 
could be applied alone or as an adjunct to systemic che-
motherapeutic agents in order to improve outcomes.
[2,3]
Patients with breast cancer with metastasis had dis-
mal 5-year survival rates of approximately 25%.[4] Of 
those, patients with liver or brain metastasis have worse 
Dr. Ozan Cem GÜLER
Başkent Üniversitesi,
Tıp Fakültesi, 
Radyasyon Onkolojisi Anabilim Dalı, 
Adana-Turkey
E-mail: ocguler@gmail.com
109Güler et al.
FDG-PET-CT in Liver Metastasis
were investigated retrospectively. Patients had LM ei-
ther at diagnosis or as a disease progression after cura-
tive treatment. Only in patients with ≤5 metastasis or 
primary tumor remained under control, SBRT to LM 
was performed. Patient selection criteria included max-
imum LM diameter <6 cm, Karnofsky Performance 
Status ≥70, normal coagulation function tests, Child–
Pugh Status A–B, and life expectancy >3 months. The 
FDG-PET-CT was performed in all of the patients be-
fore liver SBRT and a median of 4.1 (2.2–8.2) months 
after completion of liver SBRT. Treatment response 
was performed according to “PET Response Criteria 
in Solid Tumors” (PERCIST) for all patients [16] (Fig. 
1). Complete metabolic response (CMR) was accepted 
if all FDG-avid lesions disappeared. Significant reduc-
tion in the standardized uptake values (SUVs) was 
accepted as partial metabolic response (PMR). Stable 
(SMD) or progressive metabolic disease (PMD) was 
accepted if there was no visible change or unequivocal 
progression of the primary tumor.
FDG-PET-CT
Patients were imaged using a dedicated PET/CT sys-
tem (Discovery-STE 8; General Electric Medical Sys-
tem, Milwaukee, WI, USA) as previously described.
[17] Briefly, patients fasted for at least 6 h before intra-
venous administration of 370 to 555 MBq (10Y15 mCi) 
FDG. Pre-injection blood glucose levels were mea-
sured to ensure that they were <150 mg/dL. During the 
distribution phase, patients were in supine position in 
a quiet room. Combined image acquisition started 60 
min after FDG injection. Patients were scanned on a 
flat-panel carbon fiber composite table insert. First, an 
unenhanced CT scan (5-mm slice thickness) from the 
base of the skull to the inferior border of the pelvis was 
outcomes compared with bone or lung metastasis, 
with a median survival of 4–8 months if left untreated.
[5,6] Oligometastatic state is common in patients with 
breast cancer, and the outcomes of these patients are 
better than those with diffuse metastatic disease with 
effective local and systemic treatment strategies.[7] 
Furthermore, the innovations of imaging modalities 
led to early diagnosis of patients with oligometastasis 
that may potentially improve treatment outcomes.[7]
Although RT had been used only for palliative in-
tent in patients with metastasis previously, the role of 
RT had been evolved from palliative to curative ap-
proach especially in patients with oligometastasis. Ste-
reotactic body radiotherapy (SBRT) is a high precision, 
non-invasive RT technique that allows higher radiation 
doses with a steep dose gradient and could be deliv-
ered safely to the liver without causing functional com-
promise.[8] The feasibility of SBRT for LM had been 
shown in various trials, with reported local control 
(LC) rates up to 90% per acceptable toxicity.[9–12]
The prognostic value of 18-fluorodeoxyglucose 
positron emission tomography and computed tomog-
raphy (FDG-PET-CT) had been shown in various tu-
mor types.[13–15] However, its role in patients with 
oligometastatic breast cancer liver metastasis (BCLM) 
treated with SBRT is still under investigation. Hence, 
we sought to investigate the impact of metabolic re-
sponse measured by FDG-PET-CT in patients with 
BCLM treated with SBRT and systemic treatment.
Materials and Methods
Patients
The medical records of 17 patients with BCLM treated 
with SBRT between March 2013 and October 2017 
Fig. 1. (a) The positron emission tomography (PET-CT) images of a representative patient demonstrating liver metastasis 
with SUVmax of 12.4. (b) Complete metabolic response observed at PET-CT images obtained 3.4 months after 
completion of liver stereotactic radiotherapy.
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obtained using a standardized protocol (140 kV and 
80 mA). The subsequent PET scan was acquired in a 
three-dimensional mode from the base of the skull to 
the inferior border of the pelvis (6–7 bed positions, 3 
min per bed position) without repositioning the pa-
tient on the table. CT and PET images were obtained 
with the patient breathing shallowly. Attenuation was 
corrected using the CT images. Areas of FDG uptake 
were categorized as malignant based on location, in-
tensity, shape, size, and visual correlation with CT im-
ages to differentiate physiological uptake from patho-
logical uptake.
SBRT technique
Patients underwent 1.25 mm multislice contrast-en-
hanced planning CT from tracheal bifurcation to the 
lower border of the kidneys for simulation (Optima 580; 
GE Healthcare, Waukesha, WI, USA). Patients were po-
sitioned supine with arms above the head and immo-
bilized using a BodyFIX® bluebag with vacuum wrap 
(Elekta, Stockholm, Sweden). In addition, an abdominal 
compress was used to minimize organ motions.
Magnetic resonance imaging and FDG-PET-CT 
were fused with planning CTs to help the clinicians to 
localize the target volume precisely, where appropriate. 
Gross tumor volume (GTV) included the visible tumor 
in imaging, but no clinical tumor volume was defined. 
Planning tumor volume (PTV) was expanded 7 mm 
in all directions except for 12 mm craniocaudal mar-
gin.[12,18] No fiducial markers were implanted before 
treatment planning.
A healthy liver was calculated as liver volume mi-
nus GTV. In addition to the liver, other organs at risk 
(OARs) under consideration were the spinal cord, kid-
neys, stomach, duodenum, heart, small bowel, esopha-
gus, and ribs according to the location of the lesion. 
The prescribed dose was 54 Gy delivered in three frac-
tions, and the dose was prescribed to 90% isodose line. 
Treatment was delivered every other day. PTV cover-
age was aimed at >95% of the prescribed dose (Fig. 2).
Plans were calculated by the Monaco Treatment 
Planning System (Elekta Ltd., Crawley, UK) using the 
Monte Carlo algorithm and a sliding window multileaf 
collimator delivery technique. All treatment plans were 
performed for delivery using an Axesse linear accelera-
tor (Elekta AB, Stockholm, Sweden). Volumetric mod-
ulated arc therapy plans consisted of double or triple 
360° arcs.
Previously published OAR dose constraints during 
liver SBRT were used.[12,19] At least 700 mL of healthy 
liver should receive <15 Gy in three fractions. Other 
dose constraints of OARs included total kidney vol-
ume <15 Gy (volume receiving 15 Gy should be <35%), 
maximum dose (D1cc) for spinal cord <18 Gy, D1cc 
for duodenum <21 Gy, D1cc for small bowel <21 Gy, 
D1cc for esophagus <21 Gy, D1cc for stomach <21 Gy, 
D1cc for heart <30 Gy, and D1cc for ribs <30 Gy.
Statistical analysis
Statistical analyses were performed using the SPSS 22.0 
software (SPSS, Chicago, IL, USA). The LC, overall sur-
vival (OS), and progression-free survival (PFS) rates 
a
b
Fig. 2. The images of a representative patient at axial, coronal, and sagittal images demonstrating (A) 95% and (B) 50% of 
isodose of prescribed doses.
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had LM during the follow-up period. Eleven (65%) pa-
tients had only LM, whereas 6 (35%) patients had more 
than one metastatic site. LM was observed at a median 
of 28.3 (0–104.5) months.
After a median follow-up time of 11.5 (3.2–48.9) 
months, 9 (53%) patients had distant disease recur-
rence. Disease progression was observed at a median 
of 8 (0.8–32.8) months after completion of liver SBRT. 
At the last follow-up, 1 (6%) patient was alive with no 
evidence of disease, 9 (53%) patients were alive with 
disease, and 7 (41%) patients died due to disease pro-
gression. The 1- and 2-year OS rates were 68% and 
57%, respectively, and the 1- and 2-year PFS rates were 
38% and 25%, respectively (Fig. 3).
There were no grade 4 or 5 toxicities observed. 
However, mild to moderate dizziness was seen during 
the SBRT period and disappeared at the end of treat-
ment. Furthermore, there was no radiation-induced 
liver disease observed.
PET analysis
The median pre-SBRT SUVmax of LM was 6.88 (range: 
4.06–16.10), and the median post-SBRT SUVmax was 
0 (range: 0–5.30). There was a significant difference be-
tween pre- and post-SBRT SUVs (p<0.001). CMR was 
observed in 14 (82%) patients, PMR was observed in 2 
(12%) patients, and SMD/PMD was observed in 1 (6%) 
patient at post-treatment PET-CT.
were calculated using the Kaplan–Meier analyses. OS 
was defined from the date of LM diagnosis until death 
or the last follow-up visit, and PFS was calculated as 
the time between LM diagnosis time and any disease 
progression or death. Local failure was scored accord-
ing to the PERCIST criteria. Statistical analysis was 
performed to compare the initial SUV with the values 
after SBRT. All p-values reported are two-sided. A p-
value <0.05 was considered significant.
Results
Clinical characteristics
All patients were female, and the median age was 44 
(27–67) years. The primary tumor histology was inva-
sive ductal carcinoma. Mastectomy was performed in 
all patients. Fifteen (88%) patients received postopera-
tive RT for primary tumor. Three (18%) patients were 
treated with neoadjuvant systemic therapy prior to sur-
gery, whereas 14 (82%) patients received postoperative 
systemic chemotherapy. The immunohistochemical 
analysis of estrogen receptor (ER), progesterone recep-
tor [20], and cerb-B2 for the entire cohort revealed that 
14 (82%) patients had ER (+), 10 patients had PR (+), 
and 5 (29%) patients had cerb-B2 (+) disease. Only 1 
(6%) patient had triple negative disease.
Patient outcomes and survival
Table 1 shows the patient characteristics. Three (18%) 
patients had de novo LM, whereas 14 (82%) patients 
Table 1 Patient characteristics
Patient Age Tumor LM Other Primary Adjuvant OS PFS
  (years) stage timing metastatic sites treatment treatment (months) (months)
1  27 TxNx de novo Lung S, C, R C 4.90 .83
2  31 T2N1 progression Bone S, C, R C, H 15.43 9.10
3  32 T2N3 progression Lung S, C, R Xeloda 48.87 12.63
4  34 T2N2 progression Bone S, C C 8.97 8.97
5  36 T4N1 progression Lung S, C, R C 6.87 6.87
6  37 T2N3 progression Bone S, C, R C 11.87 1.67
7  38 TxN2 progression Bone S, C, R C 7.47 7.47
8  40 T2N2 progression Bone S, C C, H 32.77 32.77
9  44 T3N2 progression Lung S, C, R H 25.87 9.70
10  49 T1N0 (bilat.) progression None S, C, R Vinorelbin 8.93 6.20
11  52 T3N1 progression Bone S, C, R C 11.17 10.63
12  52 T2N2 progression None S, C, R C, H 25.83 3.90
13  52 T2N3 progression Bone S, C, R C 5.83 5.83
14  55 T3N0 progression None S, C, R - 12.83 12.83
15  63 TxN2 progression Bone S, C, R C, H 3.20 3.20
16  65 TxN2 progression Lung S, C, R xeloda 11.53 11.53
17  67 TxN2 progression Lung S, C, R H 28.70 8.03
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Discussion
In the current study, we demonstrated that PET-CT is 
an effective tool for response monitoring in patients 
with BCLM treated with SBRT. The 1- and 2-year OS 
rates for patients with BCLM treated with liver SBRT 
and systemic chemotherapy were 68% and 57%, re-
spectively, and the 1- and 2-year PFS rates were 38% 
and 25%, respectively. No grade 4 or 5 toxicities were 
observed. Although an excellent LC was achieved, 9 
(53%) patients had distant disease progression in a me-
dian of 8 months after liver SBRT.
The most common metastatic sites for patients with 
breast cancer are the bones, lungs, liver, and brain. LM 
may be observed as the de novo or as the site of recur-
rence in approximately 15% of patients.[4] In a “Sur-
veillance Epidemiology and End Results” database, Wu 
et al.[4] demonstrated that patients with BCLM have 
worse outcomes compared with lung or bone metas-
tasis. Additionally, patients with recurrences isolated 
to limited number of organs (<5), so called as oligo-
metastasis, are considered to have better prognosis.
[21] Oligometastasis has been first described by Hell-
man et al. in 1995.[21] Aggressive local treatments to 
oligometastatic sites may potentially reduce the risk of 
metastatic disease by removing the metastasis source, 
thereby improving outcomes.[22,23] Surgery, RFA, 
TACE, and RT are local treatment options for patients 
with oligometastasis.[6,24–26] Although surgery re-
mains the treatment of choice in patients with BCLM, 
it could be applied only for a selective cohort of patients 
due to morbidity and mortality risks. TACE is a less in-
vasive local treatment compared with surgery, and its 
efficacy for LC has been confirmed.[27] The reported 
OS, median disease-free survival, and response rates 
after TACE were 7.3–47.0 months, 2.9–17 months, 
and 7%–74%, respectively. Pooled grade 3–4 side ef-
fects were reported up to 17%.[27] The efficacy of RFA 
had been shown in various trials in the management of 
LM.[28–30] The response rates after RFA were 63%–
97%, and the 5-year survival rates ranged from 27% to 
30%. Although RFA is a minimally invasive method as 
an alternative to surgery, the reported morbidity and 
mortality rates were 9%–10% and 0.3%–2.2%, respec-
tively [28–30]. In our study, no patients experienced 
grade 4 or 5 toxicities, and our data on toxicity are con-
sistent with the literature.
SBRT offers an alternative, non-invasive, and con-
servative approach for LM treatment. Several prospec-
tive and retrospective studies demonstrated the feasi-
bility of SBRT for LM.[3,8–12,25] In these studies, LMs 
were treated in 1–12 fractions to a total dose of 18–60 
Gy. The 2-year LC rates ranged from 66% to 90%, and 
the 2-year OS rates were 32%–81%. Nevertheless, dif-
ferent patient selection, different histologies, and extra-
hepatic metastasis could cause the changes in OS and 
LC. In our study, patients with BCLM received 54 Gy 
in three fractions in a homogeneous group of cohort 
and dose-fraction schedule. The 1- and 2-year OS and 
PFS rates were 68% and 57% and 38% and 25%, respec-
tively.
The utility of PET-CT for assessing outcomes in 
patients with oligometastasis treated with SBRT was 
initially investigated by Solanki et al.[31] After a me-
dian follow-up of 14 months, they reported that PET 
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Fig. 3. Kaplan–Meier curves demonstrating (a) overall survival and (b) progression-free survival.
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response to SBRT enables metabolic tumor response 
in tumors non-measurable by CT, and higher SBRT 
doses correlate with long-term PET response in 31 pa-
tients with 58 lesions. Fendler et al.[20] investigated 80 
patients with LM from colorectal cancer treated with 
90Y radio embolization. They found that patients with 
a change in metabolic tumor volume or total lesion 
glycolysis have significantly longer survival than those 
without changes in PET parameters (92 vs. 49 weeks, 
p=0.006 and 91 vs. 48 weeks, p=0.025, respectively).
[20] The changes in SUVmax in PET-CT in LM were 
investigated by Stinauer et al.[32] They reported that 
the estimated SUVmax decay half-time is 2 months. In 
our study, there was a significant difference between 
pre-SBRT SUV of LM 6.88 (range: 4.06–16.10) and 
post-SBRT SUV 0 (range: 0–5.30) (p<0.001). CMR was 
observed in 14 (82%) patients, PMR was observed in 2 
(12%) patients, and SMD/PMD was observed in 1 (6%) 
patient at post-treatment PET-CT.
Our study has several limitations while interpreting 
the results. First, the retrospective nature of the study 
is the main limitation that may cause an inherent bias. 
Second, a small sample size restrained us from defin-
ing the prognostic factors affecting OS and PFS. Third, 
the follow-up time is relatively short for accurate deci-
sions. Finally, the systemic treatment varied both be-
fore and after liver SBRT and absolutely influenced the 
treatment outcomes. Nevertheless, the present study is 
important because we analyzed only BCLM, only one 
type of dose fractionation with the same SBRT tech-
nique in each patient.
Conclusion
To the best of our knowledge, this is the first study to 
evaluate the impact of metabolic response measured 
by FDG-PET-CT in patients with BCLM treated with 
SBRT. SBRT is a conservative approach with similar LC 
rates compared with other invasive/minimally invasive 
local treatments with better toxicity profile. PET-CT 
is an effective tool for evaluating treatment response 
in patients with oligometastasis. Prospective trials are 
warranted for future directions and accurate decisions.
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